Specifically, NAV3 expression is significantly lower in high‐grade gliomas (grade 4 astrocytoma and glioblastoma) compared to lower‐grade tumors (oligodendroglioma and grade 2 or 3 astrocytoma) (Figures 1B and S1A). Here, NAV3 is linked to central nervous system cancer.